Crispr Therapeutics AG vs Tencent Music Entertainment Group - ADR — how do they compare? Crispr Therapeutics AG trades at $53.68 (market cap $4.88B), while Tencent Music Entertainment Group - ADR trades at $8.39 (market cap $12.83B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 2.6× Crispr Therapeutics AG's market cap, and Tencent Music Entertainment Group - ADR pays a 3.02% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Tencent Music Entertainment Group - ADR for 67 Days on average.
| CRSP | TME | |
|---|---|---|
Market Cap | $4.88B | $12.83B |
Volume | 2,861,747 | 3,618,478 |
Sector | Health | Media |
52-Week High | $74.92 | $23.71 |
52-Week Low | $44.34 | $7.74 |
Typical Hold Time | 77 Days | 67 Days |
Enterprise Value | $3.30B | $10.77B |
Dividend Yield | — | 3.02% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
TME trades at $8.38, up 4.88% today, but technical indicators are bearish overall. The company reported strong 2025 results with revenue of $32.9B and net income of $11.06B, though recent quarters show mixed earnings performance. Analyst sentiment is mixed with a consensus price target of $12.50, and the stock appears undervalued with a P/E of 9.33 and P/S of 2.46.
The outlook is balanced: attractive valuation and profitability support upside potential, but bearish technicals, competitive pressures, and recent net cash outflows pose risks. Investors should weigh strong fundamentals against near-term headwinds and market sentiment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →